Patents Issued in September 27, 2018
  • TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES
    Publication number: 20180271954
    Abstract: The invention generally relates to compositions and methods for targeted delivery of a Cas endonuclease or nucleic acid encoding a Cas endonuclease to a fusion sequence in a cancer cell but not in a healthy cell of a subject. The Cas endonuclease or nucleic acid encoding the Cas endonuclease may be complexed with a guide RNA complementary to a fusion sequence identified based on differences between a mutated sequence obtained from a cancer cell and a wild-type sequence obtained from a healthy cell of the subject. For example, the Cas endonuclease may be a Cas9 and cut DNA or a Cas13a and cut RNA. The Cas endonuclease complexes may induce cell death or cancerous cells or cause other beneficial effects.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 27, 2018
    Inventor: Anthony P. Shuber
  • ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM
    Publication number: 20180271955
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271956
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • METHODS TO TREAT CEROID LIPOFUSCINOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS
    Publication number: 20180271957
    Abstract: A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Inventors: R. Scott McIvor, Lalitha R. Belur, Walter Low, Carolyn Fairbanks, Karen Kozarsky
  • COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISEASES
    Publication number: 20180271958
    Abstract: Use of activated protein C (APC) for treatment and prevention of ocular diseases, disorders or conditions associated with retinal leakage and CNV such as age-related macular degeneration, optionally in combined therapy with anti-angiogenesis, anti-inflammatory, immunosuppressive, and anti PDGF agent.
    Type: Application
    Filed: January 12, 2016
    Publication date: September 27, 2018
    Inventors: Dov WEINBERGER, Tami LIVNAT, Yael NISGAV
  • SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180271959
    Abstract: A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventor: Terrence J. Hunt
  • METHOD TO TREAT CANCER USING ARGININE DELPETOR AND ORNITHINE DECARBOXYLASE (ODC) INHIBITOR
    Publication number: 20180271960
    Abstract: One example embodiment is a method of treating lung carcinoma in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of an arginine reducing compound and a therapeutically effective amount of an ornithine decarboxylase (ODC) inhibitor to provide a combination therapy that has a synergistic therapeutic effect compared to an effect of the arginine reducing compound and an effect of the ODC inhibitor, in which each of the arginine reducing compound and the ODC inhibitor is administered alone.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 27, 2018
    Inventors: Ning Man CHENG, Kin Pong U, Sze Kwan LAM, Chung Man HO
  • METHODS FOR INDUCING SELECTIVE APOPTOSIS
    Publication number: 20180271961
    Abstract: Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 27, 2018
    Inventor: Malcolm K. BRENNER
  • Peptide Conjugated Particles
    Publication number: 20180271962
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: March 15, 2018
    Publication date: September 27, 2018
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • CANCER VACCINE FOR CATS
    Publication number: 20180271963
    Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof.
    Type: Application
    Filed: March 26, 2018
    Publication date: September 27, 2018
    Applicant: INVECTYS
    Inventors: Pierre LANGLADE DEMOYEN, Simon Wain-Hobson, Christelle LIARD
  • NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN
    Publication number: 20180271964
    Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Applicant: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Jochen Probst
  • UTILIZATION OF RECOMBINANT INFLUENZA VIRUSES AND MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 AND SAG2 SURFACE PROTEINS, AS VACCINES AGAINST TOXOPLASMOSIS
    Publication number: 20180271965
    Abstract: The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAGI (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 27, 2018
    Inventors: Ricardo Tostes GAZZINELLI, Rafael Polidoro Alves BARBOSA, Braulia Costa CAETANO, Alexandre de Magalhaes Vieira MACHADO, Oscar BRUNA-ROMERO, Flavio Fonseca GUIMARAES, Erica Araujo MENDES
  • Live Attenuated Heterologous Vaccine for Leptospira
    Publication number: 20180271966
    Abstract: The present invention provides compositions or vaccines that contain a recombinant or an attenuated Leptospira interrogans that elicit an immune response in animals against Leptospira infection, including compositions comprising said recombinant or attenuated L. interrogans, methods of vaccination against Leptospira, and kits for use with such methods and compositions.
    Type: Application
    Filed: October 5, 2016
    Publication date: September 27, 2018
    Inventors: Natalia Ines Bomchil, Lionel Pierre Cupillard, Celia Fontana, Pierre-Michel Guigal, Jerome Bouvet, Mathieu Picardeau, Angeli Kodjo
  • OUTER MEMBRANE VESICLES AND USES THEREOF
    Publication number: 20180271967
    Abstract: The disclosure relates to outer membrane vesicles from Francisella and Piscirickettsia, and their use in vaccine compositions. In particular, the present disclosure relates to compositions and methods useful in inducing protective immunity against francisellosis or salmon rickettsial septicaemia (SRS) in fish.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 27, 2018
    Inventors: Hanne WINTHER-LARSEN, Espen BRUDAL, Duncan COLQUHOUN
  • Conjunctivitis Vaccines
    Publication number: 20180271968
    Abstract: Compositions comprising antigenic peptides, and their use in inducing an immunoprotective response in a subject against an infection with Streptococcus pneumonia, or for treating or preventing, i.e., reducing risk of, an infection of Streptococcus pneumonia.
    Type: Application
    Filed: November 10, 2015
    Publication date: September 27, 2018
    Inventors: Michael Valentino, Michael S. Gilmore
  • STREPTOCOCCUS SUIS POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION
    Publication number: 20180271969
    Abstract: The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 27, 2018
    Applicants: Boehringer Ingelheim Vetmedica, Inc., Université de Montréal, Université du Québec à Montréal
    Inventors: Marcelo GOTTSCHALK, Guillaume GOYETTE-DESJARDINS, Jennifer Anne Kempker, Axel NEUBAUER, René ROY, Mariela SEGURA, Tze Chieh SHIAO
  • RESPIRATORY SYNCYTIAL VIRUS VACCINE
    Publication number: 20180271970
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: October 21, 2016
    Publication date: September 27, 2018
    Applicant: ModernaTX, INC.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES
    Publication number: 20180271971
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 27, 2018
    Inventors: Mary Jane CARDOSA, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES
    Publication number: 20180271972
    Abstract: Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides.
    Type: Application
    Filed: September 21, 2016
    Publication date: September 27, 2018
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Ted Milburn ROSS, Terianne Maiko WONG, Donald Martin CARTER, Jr.
  • COMPOSITIONS COMPRISING CH505 ENVELOPES, AND TRIMERS (EIGHT VALENT HIV-1 COMPOSITION AND METHODS)
    Publication number: 20180271973
    Abstract: In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens in vaccination to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogens and methods of using these comprise an immune modulating component.
    Type: Application
    Filed: December 23, 2015
    Publication date: September 27, 2018
    Inventors: Barton F. HAYNES, Hua-Xin LIAO, Bette T. KORBER, Peter T. HRABER
  • HERPES SIMPLEX VIRUS TYPE-1(HSV-1) VACCINE STRAIN VC2 GENERATING AN ANTI-EHV-1 IMMUNE RESPONSE
    Publication number: 20180271974
    Abstract: The disclosure encompasses recombinant nucleic acids comprising a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.
    Type: Application
    Filed: March 22, 2018
    Publication date: September 27, 2018
    Inventor: Konstantin G. Kousoulas
  • HUMAN CYTOMEGALOVIRUS RNA VACCINES
    Publication number: 20180271975
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: June 12, 2018
    Publication date: September 27, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • METHODS FOR GENERATING NEUTRALIZING ANTI-PATHOGEN ANTIBODIES BY DIRECTING THE HUMORAL RESPONSE TOWARD DESIRED EPITOPES
    Publication number: 20180271976
    Abstract: Methods for generating antibodies to immuno-subdominant epitopes of elusive pathogens and vaccines and methods of vaccinating subjects against elusive pathogens are disclosed. The methods include targeting immunodominant B cells to undergo apoptosis, for example, while simultaneously targeting the germinal center (GC) reaction toward preferential selection and differentiation of B cells that produce broadly neutralizing antibody against a targeted pathogen.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Murillo Lobo Gomes SILVA, Michail V. SITKOVSKY
  • METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS
    Publication number: 20180271977
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 27, 2018
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • BIOMATERIALS FOR COMBINED RADIOTHERAPY AND IMMUNOTHERAPY OF CANCER
    Publication number: 20180271978
    Abstract: Compositions and methods for the radiological and immunotherapeutic treatment of cancer are provided. Metallic nanoparticles conjugated with an immunoadjuvant are dispersed within a biodegradable polymer matrix that can be implanted in a patient and released gradually. The implant may be configured as, or be a component of, brachytherapy spacers and applicators, or radiotherapy fiducial markers. The composition may be combined with marginless radiotherapy, allowing for lower doses of radiation and enhancing the immune response against cancer, including at non-irradiated sites.
    Type: Application
    Filed: August 15, 2016
    Publication date: September 27, 2018
    Applicants: Northeastern University, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Wilfred Ngwa, Rajiv Kumar, Gerassimos Makrigiorgos, Srinivas Sridhar, Stephanie Dougan
  • TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES
    Publication number: 20180271979
    Abstract: The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 27, 2018
    Applicant: Diffusion Pharmaceuticals LLC
    Inventors: John L. GAINER, Marc LANZ
  • DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION
    Publication number: 20180271980
    Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 27, 2018
    Inventors: Randice Lisa ALTSCHUL, Neil David THEISE, Razvan Andrei ENE, Myron RAPKIN, Rebecca O'BRIEN
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20180271981
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as arthritis.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventor: Herriot Tabuteau
  • LIQUID PRODUCTS HAVING INCREASED SOLIDS CONCENTRATIONS
    Publication number: 20180271982
    Abstract: The present invention discloses liquid compositions that include an active compound, water, and means for inhibiting crystal formation or precipitation of the active compound in the liquid composition.
    Type: Application
    Filed: December 12, 2015
    Publication date: September 27, 2018
    Inventors: Shireen S. Baseeth, Matthew Dyer, John Less
  • TRANSDERMAL CARRIER
    Publication number: 20180271983
    Abstract: Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 27, 2018
    Applicant: INTELLECTUAL PROPERTY ASSOCIATES, LLC
    Inventors: Bruce J. SAND, Ryan R. BEAL, Philippe H. BURNHAM
  • POLYLACTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20180271984
    Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.
    Type: Application
    Filed: February 14, 2018
    Publication date: September 27, 2018
    Applicant: UNIVERSITY OF GENEVA
    Inventors: Michael Moller, Thomas Trimaille, Robert Gurny
  • Neurotherapeutic Nanoparticle Compositions Comprising Leukemia Inhibitory Factor
    Publication number: 20180271985
    Abstract: There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of: brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Susan Marie Metcalfe, Tarek Fahmy
  • GLYCOTARGETING THERAPEUTICS
    Publication number: 20180271986
    Abstract: Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
    Type: Application
    Filed: March 19, 2018
    Publication date: September 27, 2018
    Inventors: Jeffrey A. Hubbell, David Scott Wilson
  • Controlled Cell Delivery Vehicle and Treatment of Tumours
    Publication number: 20180271987
    Abstract: The invention relates to apH mediated cell delivery vehicle comprising: a cargo or a cargo-binding molecule for binding to a cargo; a protein transduction domain; and a glycosaminoglycan (GAG) binding element, which is capable of binding to GAG on the surface of the cell, wherein the GAG binding element is a peptide which is modified to comprise one or more histidine residues which are capable of being protonated in an acidic environment. The invention further relates to the use of such a delivery vehicle including methods of treatment, such as treatment for cancer.
    Type: Application
    Filed: June 23, 2016
    Publication date: September 27, 2018
    Applicant: The University of Nottingham
    Inventor: James Dixon
  • PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
    Publication number: 20180271988
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Philip S. LOW, Sumith A. KULARATNE
  • PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
    Publication number: 20180271989
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Philip S. LOW, Sumith A. KULARATNE
  • PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
    Publication number: 20180271990
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Philip S. LOW, Sumith A. KULARATNE
  • CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
    Publication number: 20180271991
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 27, 2018
    Inventors: Iontcho Radoslavov VLAHOV, Joseph Anand REDDY, Alicia BLOOMFIELD, Ryan DORTON, Melissa NELSON, Marilynn VETZEL, Christopher Paul LEAMON
  • TREATMENT OF HIGH TROP-2 EXPRESSING TRIPLE NEGATIVE BREAST CANCER (TNBC) WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES HOMOLOGOUS RECOMBINATION REPAIR (HRR) RESCUE MEDIATED BY RAD51
    Publication number: 20180271992
    Abstract: The present invention relates to treatment of Trop-2 positive cancers with the combination of anti-Trop-2 ADC and a Rad51 inhibitor. Preferably the drug conjugated to the antibody is SN-38, and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the combination of ADC and Rad51 inhibitor can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the combination is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 27, 2018
    Inventors: Thomas M. Cardillo, David M. Goldenberg
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20180271993
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: June 6, 2018
    Publication date: September 27, 2018
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • ANTI-MUC18 HUMAN IMMUNOTOXIN AND APPLICATIONS THEREOF
    Publication number: 20180271994
    Abstract: An anti-MUC18 immunotoxin including an anti-MUC18 single-chain variable fragment (scFv) with a nucleotide sequence as set forth in SEQ ID No. 3, and a truncated Pseudomonas exotoxin A (PEA) with a nucleotide sequence as set forth in SEQ ID No. 5. The truncated PEA may be conjugated with the scFv through a connector.
    Type: Application
    Filed: May 27, 2018
    Publication date: September 27, 2018
    Inventors: Foroogh Nejatollahi, Mozafar Mohammadi
  • A PROTEIN CONJUGATE COMPRISING MULTIPLE PHYSIOLOGICALLY ACTIVE POLYPEPTIDES AND AN IMMUNOGLOBULIN FC REGION
    Publication number: 20180271995
    Abstract: The present invention relates to a physiologically active polypeptide conjugate comprising multiple physiologically active polypeptides and immunoglobulin Fc regions, use thereof, and a preparation method thereof.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 27, 2018
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jong Soo LEE, Seong Ho CHOI, Jae Hyuk CHOI, Sang Yun KIM, Sung Youb JUNG, Se Chang KWON
  • COMBINATION THERAPIES OF HER2-TARGETED ANTIBODY-DRUG CONJUGATES
    Publication number: 20180271996
    Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 27, 2018
    Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.
    Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
  • Methods and Reagents to Treat Tumor and Cancer
    Publication number: 20180271997
    Abstract: This disclosure provides reagent to treat tumor and cancer, and methods of using the same for treating tumor and cancer. One type of the reagent is pro-antibody, which is antibody that can be activated in tumor. Another type of the reagent is a conjugate of sialidase with affinity ligand that can bind to immuno cell surface or a conjugate of sialidase with affinity ligand that can bind to another antibody, therefore provide a sialidase based cancer immuno therapy strategy.
    Type: Application
    Filed: June 10, 2018
    Publication date: September 27, 2018
    Inventor: Tianxin Wang
  • DISULFIDE-STABILIZED FABS
    Publication number: 20180271998
    Abstract: Provided are antibody fragments (Fabs) wherein native disulfide bonds are absent and engineered disulfide bonds have been introduced. Some fragments comprise further additional beneficial mutations. The fragments exhibit immuno specific binding and desirable stability properties, e.g., the fragments can be efficiently conjugated to effectors at high temperatures (e.g., >60° or >70° C.) without denaturing.
    Type: Application
    Filed: December 5, 2016
    Publication date: September 27, 2018
    Inventors: Daryl C. DRUMMOND, Melissa GEDDIE, Dmitri B. KIRPOTIN, Alexey Alexandrovich LUGOVSKOY
  • Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same
    Publication number: 20180271999
    Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.
    Type: Application
    Filed: October 25, 2017
    Publication date: September 27, 2018
    Inventors: Jae Hyun Kim, Su Kyung Lee, Won Kyu Choi, Jong Lae Lim, Soon Kil Ahn, Hee Jong Shin, Chung Il Hong
  • HOMOLOGOUS RECOMBINATION IN MULTIPOTENT ADULT PROGENITOR CELLS
    Publication number: 20180272000
    Abstract: The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or therapeutic protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: September 27, 2018
    Applicants: ABT Holding Company, Regents of the University of Minnesota
    Inventors: Catherine M. Verfaillie, Uma Lakshmipathy
  • ANTI-CANCER AND ANTI-INFLAMMATORY THERAPEUTICS AND METHODS THEREOF
    Publication number: 20180272001
    Abstract: The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of ?-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/?-catenin signaling pathway that governs the quantity of ?-catenin delivered to the cell nucleus. This intracellular inhibitor of ?-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures ?-catenin destined for the nucleus in a complex with ?-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.
    Type: Application
    Filed: October 18, 2016
    Publication date: September 27, 2018
    Inventors: Jack L. Leonard, Karl J. Simin, Deborah M. Leonard
  • Biodegradable Lipids for Delivery of Nucleic Acids
    Publication number: 20180272002
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Inventors: Frank DeRosa, Michael Heartlein
  • Biodegradable Lipids for Delivery of Nucleic Acids
    Publication number: 20180272003
    Abstract: The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R1 independently is defined herein; and a liposome composition comprising the cationic lipid of formula I or a sub-formula thereof, and methods of delivering agents, such as nucleic acids including mRNA, in vivo, by administering to a subject the liposome comprising the cationic lipid of formula I or a sub-formula thereof, where the agent is encapsulated within the liposome.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Inventors: Frank DeRosa, Michael Heartlein